Date | Open(₹) | High(₹) | Low(₹) | Close(₹) | No. Of Trades(₹) | Total Turnover(₹) | Deliverable Quantity(₹) |
|---|---|---|---|---|---|---|---|
23-DEC-2024 | 3,450 | 3,476.45 | 3,378.8 | 3,420.35 | 17,899 | 49,96,00,563.4 | 48,632 |
24-DEC-2024 | 3,421 | 3,455.25 | 3,362 | 3,399.45 | 16,124 | 24,92,51,963.05 | 28,594 |
26-DEC-2024 | 3,399.45 | 3,433.2 | 3,377 | 3,421.35 | 17,433 | 41,62,79,258.35 | 45,820 |
27-DEC-2024 | 3,421.35 | 3,446.05 | 3,396.5 | 3,405.1 | 17,456 | 75,50,38,124.75 | 1,27,828 |
30-DEC-2024 | 3,405 | 3,422.3 | 3,348.05 | 3,369.5 | 53,841 | 3,51,08,96,829.95 | 7,81,365 |
31-DEC-2024 | 3,362.2 | 3,396.7 | 3,343.95 | 3,360.05 | 24,666 | 51,66,05,022.55 | 89,110 |
01-JAN-2025 | 3,368.15 | 3,434.2 | 3,340.15 | 3,418.55 | 23,741 | 59,19,93,061.65 | 92,288 |
02-JAN-2025 | 3,425.35 | 3,452 | 3,361.5 | 3,441.55 | 19,515 | 58,73,45,898.75 | 1,09,900 |
03-JAN-2025 | 3,450 | 3,465 | 3,378.5 | 3,402.85 | 26,857 | 63,03,39,877.55 | 91,659 |
06-JAN-2025 | 3,402.85 | 3,418.55 | 3,342.9 | 3,362.95 | 21,793 | 44,69,13,756.5 | 67,051 |
07-JAN-2025 | 3,380 | 3,443.5 | 3,351.55 | 3,404.1 | 22,580 | 45,92,03,088.25 | 67,479 |
08-JAN-2025 | 3,409.9 | 3,417.05 | 3,318 | 3,324.75 | 27,264 | 56,10,74,419.1 | 1,07,388 |
09-JAN-2025 | 3,299.95 | 3,334.35 | 3,285.15 | 3,321.55 | 24,834 | 60,98,85,989.95 | 1,16,166 |
10-JAN-2025 | 3,325 | 3,350.15 | 3,264.1 | 3,274.45 | 24,659 | 47,08,80,234.35 | 67,630 |
13-JAN-2025 | 3,241.65 | 3,294.15 | 3,229.4 | 3,235.35 | 24,539 | 47,66,74,884.75 | 88,952 |
14-JAN-2025 | 3,239.7 | 3,265 | 3,214.7 | 3,252.4 | 23,613 | 47,89,23,590.2 | 89,554 |
15-JAN-2025 | 3,269.8 | 3,269.8 | 3,180.3 | 3,215.05 | 26,830 | 65,94,24,027.2 | 1,20,847 |
16-JAN-2025 | 3,224 | 3,244 | 3,151.85 | 3,178.6 | 49,816 | 79,15,26,481.5 | 1,59,593 |
17-JAN-2025 | 3,163.2 | 3,201.25 | 3,152.2 | 3,174.85 | 34,042 | 70,71,42,963.95 | 1,44,838 |
Empagliflozin is a new sodium-glucose co-transporter-2 (SGLT-2) inhibitor approved for glycemic management in individuals with type 2 diabetes.
The USFDA examined Torrent's manufacturing plant in Pithampur during the September quarter and issued a Form 483 with one observation.
The business reported a 13% growth in India revenues to ₹1,632 Crore, driven by outperformance in focus therapies.
When compared to the previous quarter, revenue growth was modest at 1.05%, while net profits experienced a slight decline of 0.88%.
In August, the CDSCO banned more than 156 fixed-dose combination medications from the Indian market.
Here are some of the stocks that may see significant price movement today: Nuvama Wealth, RITES, Torrent Pharmaceuticals, etc.
The company announced that its India business grew by 10% year on year in the June quarter, with sales rising to ₹1,635 Crore from ₹1,426 Crore in Q1 FY24.
Here are some of the stocks that may see significant price movement today: Hindustan Unilever, Bajaj Finance, Vedanta, etc.
Invest wise with Expert advice
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2025, IIFL Capital Services Ltd. All Rights Reserved
IIFL Securities Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
